WO2004045533A2 - Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs - Google Patents

Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs Download PDF

Info

Publication number
WO2004045533A2
WO2004045533A2 PCT/US2003/036686 US0336686W WO2004045533A2 WO 2004045533 A2 WO2004045533 A2 WO 2004045533A2 US 0336686 W US0336686 W US 0336686W WO 2004045533 A2 WO2004045533 A2 WO 2004045533A2
Authority
WO
WIPO (PCT)
Prior art keywords
inherent
ring system
chemical
phenyl ring
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036686
Other languages
French (fr)
Other versions
WO2004045533A3 (en
Inventor
Paul W. Erhardt
Moustafa M. Aouthmany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toledo
Original Assignee
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toledo filed Critical University of Toledo
Priority to AU2003291007A priority Critical patent/AU2003291007A1/en
Priority to JP2004553810A priority patent/JP2006508984A/en
Priority to EP03783592A priority patent/EP1565178A2/en
Priority to CA002503312A priority patent/CA2503312A1/en
Publication of WO2004045533A2 publication Critical patent/WO2004045533A2/en
Publication of WO2004045533A3 publication Critical patent/WO2004045533A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Definitions

  • Fig. 2 shows Structure 4 which is 2,6-bis(1-pyrroIidinylmethyl)-4- benzamidophenol, an antiarrhythmic drug candidate.
  • Structure 5 represents a series of external ester-containing derivatives of 4 that provides a ⁇ complimentary family of potential soft drug versions of the parent having variously shortened durations of action.
  • A may be deleted because B or both B and C are already present as an inherent portion of the parent structure.
  • B is substituted phenyl
  • C is ethyl
  • D is carboxyl
  • E is methyl
  • Structure 6 defines the southern portion of Structure 2 plus its
  • the programmed rate of metabolism of the modified drug is matched with a release rate from a sustained-released injectable formulation or implant of the modified drug to provide for prolonged steady-state levels of the modified drug at pre- calibrated concentrations.
  • Still further uses of the method of the present invention include uses in which the parent drug plus the added chemical arrangement comprises an ultra-short acting antibiotic compound including sulfonamide, penicillin, ampicillin, cephalosporin or tetracycline.
  • the ultra- short acting antibiotic compounds are administered via their impregnation in surgical suture material or wound-healing implantable polymeric materials.
  • Figures 8 and 9 represent metabophore- containing, bulky analogs of decamethonium and pancuronium, respectively.
  • Two external esters have been deployed in each case in order to further enhance the overall molecules' metabolic biotransformations given that these esters' close placements to the bulky aromatic rings slow their individual metabolic hydrolyses rates.
  • X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage
  • the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting one or more of a predetermined chemical arrangement to an inherent dihydro-imidazole ring system therein.
  • the chemical arrangement comprises: ⁇ — R— X — R' where ⁇ is a phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the inherent dihydro-imidazole ring system;
  • R' is the inherent dihydro-imidazole ring system that is connected to one of oxygen atoms present in X via a 2-position carbon atom.
  • X is a carboxyl group.
  • the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting a first chemical arrangement to the inherent phenyl ring system and by connecting a second chemical arrangement to an inherent dihydro-imidazole ring system.
  • X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage in the first and second chemical arrangements;
  • the chemical arrangements comprise: R — X — R' where R is absent for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to any un- substituted carbon within the inherent phenyl ring system in the first chemical arrangement;
  • X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring system via respective carbon, sulfur or phosphorous atoms for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is connected to R via a metabolically stable linkage; and, R' is the inherent dihydro-imidazole system that is connected to one of oxygen atoms present in X via a 2-position carbon atom for the incorporation between the phenyl ring and the

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious parent drug compound so as to retain efficacy while re-directing a preferred route and rate of the parent drug compound's metabolism to an inactive or very weakly active and non-toxic metabolite are disclosed. The chemical arrangement is ϕ-R-X-R'; wherein ϕ is a phenyl, substituted aryl or heteroaryl system that is already present in the parent drug compound or is specifically added to the parent drug compound via a metabolically stable connection; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is already present in the parent drug compound or is added to the parent drug compound via a metabolically stable connection to ϕ; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via a metabolically stable connection to R; and, R' is an added alkyl, alkenyl or aralkyl group either branched or 20 unbranched containing from 1 to 10 carbons, or is a structural element already present as an inherent portion of the parent drug compound.

Description

METHOD AND COMPOSITIONS FOR TREATING PERSISTENT PULMONARY HYPERTENSION USING ARALKYL ESTER SOFT DRUGS
CROSS-REFERENCE TO RELATED APPLICATION The present invention is a continuation-in part of U.S. Serial No.
09/570,485 filed May 12, 2000, still pending, which is expressly incorporated herein by reference.
BACKGROUND OF THE INVENTION Pharmaceutical agents or drugs exhibit desirable therapeutic properties because they contain distinct molecular arrangements called pharmacophores. Oftentimes, however, the pharmacophores or the presence of other chemical components within such compounds, provide a less than ideal overall profile relative to the final deployment of a given drug for a particular clinical indication. In some cases this situation can be improved by altering chemical features associated with a drug's distribution, metabolism or elimination (DME). This process, when successful, results in what is now referred to in the pharmaceutical community as a "soft drug" version of the original or parent drug compound: Soft Drugs. XX. Design, Synthesis and Evaluation of Ultra-Short Acting beta-Blockers, H.-S. Yang, W.-M, Wu and N. Bodor, Pharm. Res.. 12, 329 (1995); and Synthesis and Enzymatic Hydrolysis of Esters, Constituting Simple Models of Soft Drugs, M. Graffner-Nordberg, K. Sjodin, A. Tunek and A. Hallberg, Chem. Pharm. Bull.. 46, 591 (1998).
However, unless there is compelling preclinical data which suggests that the clinical application of a lead compound is going to become problematic, DME-related features are typically not rigorously evaluated in a chemical manner during the early process of new drug discovery and development. This situation has arisen, in part, because substantial clinical experience is often required to accurately define the sometimes subtle parameters of an undesirable DME feature relative to the beneficial aspects of a new drug while the latter is within the close purview of its actual clinical use in a specific pathophysiological setting. The problem of not knowing exactly what DME and toxicity-related properties may need to be addressed is additionally confounded by not having ready chemical blueprints for how to generally proceed even when a particular DME or toxicity issue becomes suspected. The invention disclosed herein provides a ready method for altering
DME and toxicity-related properties by deploying a specific chemical blueprint. The approach is useful to initially assess the DME parameters for an entire family of potential new drug candidate possibilities during the family's very early stages of structural refinement and preclinical study. When applied in this fashion, the inventive method expedites and improves the efficiency of the overall process of drug discovery and development.
Technologies which can enhance the efficiency of the drug discovery and development process have recently become of very high interest to the global pharmaceutical enterprise: Lead Generation and Optimization, Annual Meeting Strategic Research Institute, San Diego, June 23, 1997; Emerging Technologies for Drug Discovery, International Biotechnology Event National Management Health Care Congress, Boston, May 19, 1997; and Pharmaceutical Education, Interim Meeting, American Association Colleges Pharmacy, Washington, D.C., March 2, 1997. Of equal significance but in more succinct and individually directed applications, the present invention is also useful for modifying the clinically established pharmaceutical agents where the specific therapeutic/side-effect details and benefits that might be associated with such DME alterations to a parent drug molecule are already recognized for a given indication. The current move to individualize drug treatment protocols within the evolving field of pharmacogenetics further underscores the very high interest and importance for having conveniently deployable technologies which can be generally applied toward fine-tuning and tailoring the overall pharmacological profile of a given drug for a given indication within a given individual: Re∞mmendations of the NIGMS Working Group-Understanding Individual Vaήations in Drug Responses: From Phenotype to Genotype, R.M. Long and R.M. Weinshilboum, NJH Report <http://www.hih.gov/nigms/news/reports/pharmacogenetics.html>, 5 pages (June 9-10, 1998).
SUMMARY OF THE INVENTION In one aspect, the present invention relates to a method of deploying one or more aralkyl ester moieties or "metabophores" within a parent drug compound. The aralkyl ester moieties are either co-constructed within the constitutive molecular framework of a parent drug compound or are added onto a parent drug compound as a distinct appendage. These constructions are done in such a manner so as to preserve the parent drug's therapeutic properties while programming a specific course for the drug's metabolism. The specific course for the drug's metabolism leads to inactive or much less active, non-toxic metabolites when the modified drug is then administered to humans by either the oral, inhalation, injection, implantable or topical routes. Furthermore, the specific molecular details of the aralkyl ester moieties and their various placements within the parent drug's structure are able to be fine-tuned to precisely control the rate of metabolism. The rate of metabolism, in turn, can be used to control the distribution, the duration of action, the elimination, and/or the toxicity of the resulting soft drug. The metabophores are useful for all drug types whenever the programmed ester cleavage causes fragmentation of the drug's inherent pharmacophore or leads to the production of an acidic group that can not somewhere by tolerated by the pharmacophore within the still intact parent drug. The metabophores are also useful for producing families of closely related compounds for better optimizing the overall pharmacological profiles of new drug candidates during the process of drug design and development.
The metabophores are also useful for enhancement of the overall therapeutic profiles for a wide variety of drugs already being used. In one aspect, the metabophores are used to program a specific course of innocuous metabolism/elimination in order to circumvent unwanted accumulation and/or toxic pathways otherwise exhibited by the parent drug. In another aspect, the metabophores are used to program the rate for a specified metabolism in order to adjust the parent drug's duration of action to a desired shorter time interval. Alternatively, when the aralkyl ester moieties are used in conjunction with an implant or drug depot delivery system, the rate of programmed metabolism can be matched to that for the soft drug's delivery so as to precisely provide prolonged steady-state levels of the soft drug at pre- calibrated concentrations.
In another aspect, the metabophores are used to program an ultra- short duration into a parent drug to allow the resulting soft drug's actions to be under precise moment-to-moment control via its intravenous administration infusion rate, an overall drug property which has already been demonstrated to be particularly useful in critical care and surgical settings. Given the paucity of drugs and drug-related technologies that have been previously targeted for very young humans, the present invention is especially useful in the development of aralkyl ester soft drugs which are conveniently and safely deployed for the specific treatment of premature, full-term newborn or for the perinatal and neonatal populations in general.
In yet another aspect, the metabophores are useful to provide an ultra- short duration drug which allows for localizing the effects of the soft drug when the drug's initial delivery or activation within a desired compartment can also be achieved in a selective manner (e.g. localized injection, implant, surgical sutures, or localized photodynamic activation).
In still yet another aspect, the metabophores are useful to provide a soft drug pharmacological agent that can be deployed by the intravenous route to wean a patient off of a parent drug whose pharmacological action is more safely removed in a controlled, step-wise manner by progressively decreasing the rate of the intravenous drip of the soft drug version (e.g. avoidance of rebound pharmacological events due to abrupt withdrawal of the parent compound). In one aspect, the present invention relates to a method and to compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious parent drug compound so as to retain efficacy while re-directing a preferred route and rate of the parent drug compound's metabolism to an inactive or very weakly active and non-toxic metabolite. The chemical arrangement comprises φ — R— -X— R' where ψ is a phenyl, substituted aryl or heteroaryl system that is already present in the parent drug compound or is specifically added to the parent drug compound via a metabolically stable connection;
R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is already present in the parent drug compound or is added to the parent drug compound via a metabolically stable connection to φ;
X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via a metabolically stable connection to R; and,
R' is an added alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons, or is a structural element already present as an inherent portion of the parent drug compound.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows Structure 1 which is propranolol, a prototypical aryloxypropanolamine beta-adrenergic receptor blocking agent which is used clinically and has a long duration of action (i.e. several hour half-life). Structure 2 is esmolol, which is also a beta-blocker used clinically (Brevibloc®) but was designed to have an ultra-short duration of action (i.e. ten minute half-life) as a result of an appended "external' ester (note carboxyl moiety extended from the southern region of the overall molecule). Structure 3 is another ultra-short acting beta-blocker which has an ester within or "internaf to the parent aryloxypropanolamine pharmacophore (note centralized location of the carboxyl moiety within the overall molecule).
Fig. 2 shows Structure 4 which is 2,6-bis(1-pyrroIidinylmethyl)-4- benzamidophenol, an antiarrhythmic drug candidate. Structure 5 represents a series of external ester-containing derivatives of 4 that provides a ■ complimentary family of potential soft drug versions of the parent having variously shortened durations of action.
Fig. 3 shows a schematic representation of the chemical elements showing a "metabophoric" blueprint for placement within clinically used drug 5 molecules and/or for elaboration within new drug candidate compounds undergoing development for use within the clinic. In Structure 6: A is an attachment or tether functionality when B is not an inherent portion of the parent drug molecule; B is an aryl or heteroaryl system; C is alkyl or an alkene chain; D is carboxyl (-CO2-), sulfoxyl (-SO3) or a phosphatyl function
10 (-PO3<); and E is alkyl, aralkyl or an additionally derivatized leaving group. In certain embodiments, A may be deleted because B or both B and C are already present as an inherent portion of the parent structure. For example, when A is absent, B is substituted phenyl, C is ethyl, D is carboxyl and E is methyl, then Structure 6 defines the southern portion of Structure 2 plus its
15 relationship to the phenyl ring in the right-half portion of the naphthalene system within Structure 1 wherein the latter is an inherent portion of the prototypical β-blocker pharmacophore. In Structure 7: E may also be (or become attached to) a required pharmacophoric component of the parent drug compound. In this embodiment, the ester metabophore D is thus 0 encompassed from both sides within the parent structure's pharmacophore (e.g. as in Structure 3 within Fig. 1) as opposed to its residence as an appendage (e.g. as in Structure 2 within Fig. 1). Thus, when A is absent, B is ortho-flurophenyl, C is absent (alkyl case -(CH2)n- where n - 0), D is carboxyl and E is a methylene attached to a portion of the parent pharmacophore, then 5 Structure 7 defines the key metabophoric placement within Structure 3 of Fig. 1.
Fig. 4 shows the structural similarities between the esmolol Structure 2, a new target molecule Structure 8, and Structure 9 which is clonidine, a prototypical ct2-adrenergic receptor agonist whose beneficial clinical effects 0 are mediated centrally. A complementary overlap involving the key elements of the partially appended (external) metabophore within Structure 2 and a significant portion of the requisite pharmacophore within Structure 9 can be found to co-reside within the phenyl-ring of Structure 8.
Fig. 5 shows a representation of the backbone chain folding of E-coli dihydrofolate reductase containing a bound methotrexate molecule as derived from a computer-generated plot of all atoms in the drug and all α-carbon atoms of the enzyme. Strands of the central pleated sheet are shown as wide arrows.
Fig. 6 shows structures of methotrexate (Structure 10) and of a metabolically labile internal ester target form (Structure 11 ), in which a simple ester bond is deployed as a metabophoric replacement for the parent structure's amide bond.
Figs. 7-25 show examples of metabophores placed within a parent molecular framework for a wide array of established pharmaceutical agents that are used clinically. Fig. 26 shows Structure I to VII which represent quickly equilibrating, short acting versions of the α-adrenergic receptor ligand tolazoline. In these structures: X = -COO-, -SO2O- or -PO(OR')O-; Y = H, CH3) OH or OR'; R' - CH3, CH2CH3 or CH(CH3)2; n = 0, 1 or 2; and, lines drawn into the central portions of either the phenyl or dihydro-imidazole ring systems indicate that the attachment of that group can occur at any one of the ring's un-substituted carbon atoms by replacement of a hydrogen atom. Structure VIII represents a specific version of I wherein X = -COO-, Y = H, R' = CH3, n = 2, and the attached group is substituted for a hydrogen atom that was bonded to the carbon atom located in the para-position of the phenyl ring system.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT In one aspect, the present invention relates to a method for programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or very weakly active and non-toxic metabolite when the parent drug compound is administered to humans by either the oral, injection, inhalation, implantable or topical routes. The method comprises modifying the parent drug compound by forming one or more of a modifying the parent drug compound by forming one or more of a predetermined chemical arrangement within the parent drug compound. The chemical arrangement comprises A— φ— (R)— X— R' where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound, φ is a substituted aryl or heteroaryl system that is already present within the parent" drug compound or is specifically added to the parent drug compound via A. R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either already present within the parent drug compound or is specifically added to the parent drug compound via connection to φ. X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R. R' is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons; other common leaving group or, a structural element already present as an inherent portion of the parent drug compound. The chemical arrangement is not used in connection with specific structural settings where the parent drug compound is an aryloxypropanolamine, a 2,6-bis(1- pyrroIidinylmethyl)-4-benzamidophenoi, or where the parent drug already contains an ester moiety as an inherent component of its structure that also causes the parent drug to already exhibit a short duration of action as would be the specific cases for the classical short-acting drugs succinylcholine and procaine.
In certain embodiments, X is carboxyl. In other embodiments, R and R' are unbranched alkyl from 1 to 2 carbons. In still other embodiments, R' is a structural element already present as an inherent portion of the parent drug.
The modified drug is used to optimize the overall pharmacological profile of a new drug candidate during the process of drug design and development. Alternatively, the modified drug is used to enhance the overall therapeutic profile of a parent drug already being used in the clinic. The programmed metabolism of the added chemical arrangement serves to circumvent unwanted accumulation of the drug and to circumvent one or more toxic metabolic pathways.
The programmed rate of metabolism for the added chemical arrangement is adjusted to produce a shorter duration of action for the modified drug as compared to the parent drug. The shorter duration allows the actions of the modified drug to be under precise moment-to-moment control by adjustment of the infusion rate of the modified drug when administered intravenously. The intravenous administration is used to treat critical care patients and to treat neonates.
The intravenous administration is also used to wean a patient off an unmodified parent drug whose similar pharmacological action is more safely removed in a controlled, step-wise manner by progressively decreasing the rate of the intravenous drip of the modified drug. The shorter duration allows the actions of the modified drug to remain localized when the initial delivery or activation of the modified drug is targeted to a specified compartment by use of localized injection or implant materials, or by localized photodynamic activation of the modified drug. In certain embodiments, the implant is a type of surgical-related material or suture where the modified drug is an antibiotic or a compound that promotes healing.
According to one aspect of the present invention, the programmed rate of metabolism of the modified drug is matched with a release rate from a sustained-released injectable formulation or implant of the modified drug to provide for prolonged steady-state levels of the modified drug at pre- calibrated concentrations.
Also, according another aspect of the present invention, the modified drug is used as a topical treatment in order to eliminate or lessen unwanted effects that the unmodified parent drug exhibits upon systemic absorption after placement on the skin or within the eye or nasal passageways.
The method of the present invention is especially useful where the parent drug plus added chemical arrangement comprises a short-acting anti-cholinergic agent. In certain embodiments, the short-acting anti- cholinergic agent is an atropine derivative that is designed for topical administration to the eye. In other embodiments, the short-acting anti- cholinergic agent is a non-depolarizing neuromuscular junction blocking agent that is designed for use by the intravenous route during surgical- related procedures.
Also, the method of the present invention is especially useful where the parent drug plus added chemical arrangement comprises an ultra-short acting alphai-adrenergic receptor blocker or an alpha2-adrenergic receptor agonist.
The method of the present invention is also useful where the parent drug plus added chemical arrangement comprises a short-acting inhibitor of the sodium channel. In certain embodiments, the short-acting inhibitors are administered as sustained-release or implantable dosage forms. Still other uses of the method of the present invention include uses in which the parent drug plus the added chemical arrangement comprises an ultra-short acting ACE inhibitor; an ultra-short acting histamine receptor blocker; an ultra-short acting adenosine antagonist; an ultra-short acting anti-inflammatory agent; an ultra-short acting antiarrhythmic agent; and, an ultra-short acting calcium channel blocker.
Still further uses of the method of the present invention include uses in which the parent drug plus the added chemical arrangement comprises an ultra-short acting antibiotic compound including sulfonamide, penicillin, ampicillin, cephalosporin or tetracycline. In certain embodiments, the ultra- short acting antibiotic compounds are administered via their impregnation in surgical suture material or wound-healing implantable polymeric materials.
Yet another use of the method of the present invention includes a use in which the parent drug plus the added chemical arrangement comprises a short-acting version of methotrexate. In certain embodiments, the short- acting version of methotrexate is administered topically. The present invention is especially useful where the topical administration is used to treat epidermoid cancers or psoriasis. In one aspect, the present invention provides a method and compositions for treating persistent pulmonary hypertension in human newborns. An intravenous infusion of a modified drug is formed by adding one or more of a predetermined chemical arrangement to an efficacious parent drug compound so as to retain efficacy while re-directing a preferred route and rate of the parent drug compound's metabolism to an inactive or very weakly active and non-toxic metabolite. The chemical arrangement comprises φ—R—X—R' . . "^ where φ is a phenyl, substituted aryl or heteroaryl system that is already present in the parent drug compound or is specifically added to the parent drug compound via a metabolically stable connection;
R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is already present in the parent drug compound or is added to the parent drug compound via a metabolically stable connection to ψ;
X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via a metabolically stable connection to R; and,
R' is an added alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons, or is a structural element already present as an inherent portion of the parent drug compound.
According to another aspect of the present invention, the parent compound comprises an alpha-adrenergic receptor ligand. In certain embodiments, the alpha-adrenergic receptor ligand has an inherent phenyl ring system and comprises tolazoline or is a derivative of tolazoline where the inherent phenyl system is also substituted with one or more methyl, hydroxy or methoxy groups in any combination of attachments to any of ortho, meta- or para- positions on the inherent phenyl ring system.
Referring now to Structures 2 and 3 in Fig. 1, the indicated metabophoric functionalities were previously incorporated into propanol-like structures to produce ultra-short acting beta-adrenergic receptor blocking agent soft drugs: Method for Treatment or Prophylaxis of tetra-substituted Cardiac Disorders (Aryl Esters), P.W. Erhardt, R.J. Borgman and J.P. O'Donnell, U.S. Patent. 4,387,103 (1983); Method for Treatment or Prophylaxis of Cardiac Disorders (Aryl Esters), P.W. Erhardt, R.J. Borgman 5 and J.P. O'Donnell, U.S. Patent. 4,593,119 (1986); Method for Treatment or Prophylaxis of Cardiac Disorders (Internal Esters), S . Kam, P.W. Erhardt, R.J. Borgman and J.P. O'Donnell, U.S. Patent. 4,405,642 (1983); Compounds and Method for Treatment or Prophylaxis of Cardiac Disorders (N-External Esters), P.S. Erhardt and R.J. Borgman, U.S. Patent. 4,450,173
10 (1984); Compounds for Treatment or Prophylaxis of Cardiac Disorders (Internal Esters), R.J. Borgman, P.W. Erhardt, ST. Kam and J.P. O'Donnell, U.S. Patent. 4,604,481 (1986); Esters of Thiadiazole Oxypropanolamine Derivatives and Pharmaceutical Uses, P.W. Erhardt and W.L. Matier, U.S. Patent. 4,623,652 (1986); Esters of 3-(3-Substituted-Amino-2-
15. Hydroxpropoxy)-4-Substituted-1,2,5-Thiadiazole Derivatives, W.L. Matier, P.W. Erhardt and G. Patil, U.S. Patent. 4,508,725 (1985); Ethylenediamine Derivatives of Aryloxypropanolamine Aryl Esters Having Various Medicinal Properties, P.W. Erhardt and CM. Woo, U.S. Patent. 4,556,668 (1985); Esters or Aryloxpropanolamine Derivatives and Medicinal Uses, P.W. 0 Erhardt and W.L. Matier, U.S. Patent. 4,692,446 (1987); Esters of Aryloxypropanolamine Derivatives, P.W. Erhardt and W.L. Matier, U.S. Patent. 4,804,677 (1989); Esters of Aryloxypropanolamine Derivatives, P.W. Erhardt and W.L. Matier, U.S. Patent. 4,906,661 (1990); Ultra-Short Acting β-Blockers: A Proposal For The Treatment of The Critically III Patient, J. 5 Zaroslinski, R.J. Borgman, J.P. O'Donnell, W.G. Anderson, P.W. Erhardt, ST. Kam, R.D. Reynolds, R.J. Lee and R.J. Gorczynski, Life Sciences. 31, 899 (1982); Benzyla ine and Dibenzylamine Revisited. Syntheses of N- Substituted Aryloxypropanolamines Exemplifying a General Route to Secondary Aliphatic Amines, P.W. Erhardt, Synth. Comm.. 13, 103 (1983); 0 Ultra Short-Acting β-Adrenergic Receptor Blocking Agents. 1. (Aryloxy)propanolamines Containing Esters in the Nitrogen Substituent, P.W. Erhardt, C . Woo, R.J. Gorczynski and W.G. Anderson. J. Med. Chem.. 25, 1402 (1982); Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function, P.W. Erhardt, CM. Woo, W.G. Anderson and R.J. Gorczynski. J. Med. Chem.. 25, 1408 (1982); and Ultra-Short-Action β-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of (Aryloxy)propanolamines Having Esters on the Aryl Function, P.W. Erhardt, CM. Woo, W.L. Matier, R.J. Gorczynski and W.G. Anderson, J. Med. Chem.. 26, 1109 (1983). The successful development and marketing of Structure 2 (esmolol or Brevibloc®) provides an exemplary clinical proof of utility for the present invention within the context of using befa-blockers in the critical care arena: Esmolol. P.W. Erhardt, in Chronicles of Drug Discovery. D. Lednicer, Ed. ACS Books, Washington, D.C, U.S.A. 1993; A Prodrug and a Soft Drug. P.W. Erhardt, in Drug Metabolism: Databases and High-Throughput Testing During Drug Design and Development. P.W. Erhardt, Ed. IUPAC Books, Blackwell Science, Oxford, U.K. 1999.
Referring to Fig. 2, the indicated metabophoric functionalities have also been previously incorporated into a novel compound, Structure 4 as the latter was undergoing preclinical and early clinical development for its potential use as a long-acting antiarrhythmic agent. A short-acting, potential soft drug version, Structure 5, was obtained in a complimentary manner within a very limited family of closely-related compounds: Ester Derivatives of 2,6-Bis(1-pyrrolidinylmethyl)-4-benzamidophenol as Short-Acting Antiarrhythmic Agents. 1. D.M. Stout, L.A. Black, C Barcelon-Yang, W.L. Matier, B.S. Brown, C.Y. Quon and H.F. Stampfli, J. Med. Chem.. 32, 1910 (1989); and Mono- and Bis(aminomethyf)phenylacelic Acid Esters as Short- Acting Antiarrhythmic Agents. 2. R.J. Chorvat, L.A. Black, V.V. Ranade, C Barcelon-Yang, D.M. Stout, B.S. Brown, H.F. Stampfli and C.Y. Quon, 1 Med. Chem.. 36, 2494 (1993). Although these research compounds were not pursued into the marketplace, the ready obtainment of a family of short- acting agents within the specific context of parent compound Structure 4 provides a demonstration of the utility and ease of deploying the metabophoric technology, as specifically described herein, in a parallel manner during the preclinical and early clinical development stages of new drug development. Referring to Fig. 3, the structural arrangements specified by
Structures 6 and 7 have similar applicability when placed within other drug molecules. Since the structural systems or chemical arrangements portrayed by Structures 6 and 7 program distinct metabolic lability into a parent molecule, they are also referred to herein as "metabophores," by analogy to the term "pharmacophore". The latter term is used to specify the structural components within a drug that are requisite for the drug's efficacious pharmacological activity. By analogy, the term "metabophore" has recently been placed within the literature to designate the specific molecular features that are pertinent for a given metabolic process, such as that for the enzymatic hydrolysis reaction of an ester moiety: Drug Metabolism Data: Past And Present Status, P.W. Erhardt, Med. Chem. Res.. 8, 400 (1998); Drug Metabolism Data: Past, Present and Future Considerations, P.W. Erhardt, Metabolism Databases and High Throuoh-put Testing During Drug Design and Development. P. Erhardt, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 1999; Statistics-Based Probabilities of Metabolic Possibilities, P.W. Erhardt, Metabolism Databases and High Throuoh-put Testing During Drug Design and Development. P. Erhardt, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 1999; and Use of Metabolism Databases During The Design of Prodrugs and Codrugs, P.W. Erhardt, Metabolism Databases and High Through-put Testing During Drug Design and Development. P. Erhardt, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 1999.
Thus, the method of the present invention provides for the general use of a distinct metabophoric chemical arrangement that is incorporated one or more times within a parent drug compound. Specifically, variations within a defined family of an aralkyl ester moiety constitute the distinct metabophoric arrangements that are incorporated one or more times into a parent drug compound such that initially there is a minimal impact upon the original desired pharmacological activity exhibited by the parent drug. The metabophore units are subject, however, to Phase 1 metabolic hydrolysis by one or more of the esterases, sulfatases, phosphatases, CYPs and the like. In Fig. 3, both the ABCD fragment and the E fragment that result from the metabolic hydrolysis are inactive or significantly less active, are non-toxic and are subject to subsequent metabolic and/or elimination pathways at a rate that is appropriate for a given clinical indication. Further, manipulation of the steric and electronically driven chemical constants associated with specific molecular aspects of the metabophore allows for precise calibration and fine-tuning of the rate of the metabolic hydrolysis reactions.
While the exact numbers and preferred chemical embodiments for the metabophores are ultimately dictated via optimization within each individual case of drug and indication, there are some arrangements which generally provide for the most chemically efficient and pharmacologically compatible deployments of the inventive method. In the case of the external esters, Structure 6, the preferred embodiment often reflects incorporation of not more than two metabophores. In addition, for the preferred embodiment A is absent, B and C are at least partially derivable from structural elements already present within the parent pharmacophore, D is a carboxylic ester and E is an alkyl group. In the most preferred general embodiment only a single metabophore is utilized, C is further specified to be one or two unsubstituted carbons distant from B, and E is further specified to be a simple methyl or ethyl group. In the case of the internal esters, Structure 7, the generally preferred embodiment involves deployment of just one metabophore, where A is absent, B and C are at least partially derivable from features already present within the parent pharmacophore or C is completely absent (alkyl ~(CH2)n- case where n = 0), D is a carboxylic ester, and E is an integral part of the inherent pharmacophore as long as its connection to D is represented by at least one, non-sterically hindered methylene unit. An arrangement which simultaneously deploys one internal ester metabophore plus one or two external ester metabophores is also a particularly useful embodiment when extremely ultra-short durations of action are being sought for a particular indication.
Referring now to Figures 4 and 6, target Structures 8 and 11 depict preferred embodiments for the respective external and internal metabophores of the inventive method as applied to two completely different types of parent molecules. To expedite drug design and development, these target structures are given the highest priority for chemical synthesis and pharmacological evaluation. Subsequent family members are constructed according to the specifications of Structures 6 and 7 on as needed basis in order to further progress and fine-tune the nature of the metabophoric insertions and to thereby best accommodate a given clinical indication. From these figures it can be noted that the present invention provides a ready blueprint for how to expeditiously address DME properties as new lead compounds proceed through the process of drug discovery and development by deploying a hierarchy of actual, practically selected, chemical structures accompanied by experimentally derived pharmacological test results. In this context the inventive method, as disclosed herein, clearly distinguishes itself form the present trend to use theoretical or computational methods accompanied by various searching paradigms across real or virtual compound libraries in order to select compounds that are then synthesized and subjected to experimental pharmacological verification, all being done in a reiterative fashion so as to finally proceed toward an applicable metabophoric lead arrangement that might then be likewise deployed via actual structures in a given, ongoing case of new drug development: e.g. Quantitative Structure-Metabolism Relationship: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of Noncongener Carboxylic Esters, P. Buchwald and N. Bodor, J. Med. Chem.. 42, 5160 (1999).
The inventive technology is further illustrated in Figs. 7-25 which show specific target structures and in the following examples which are meant to demonstrate the wide, general applicability of the invention while also providing a purview of how the metabophores can be specifically incorporated across a wide variety of structural types within the framework of actual chemical compounds. These representative examples are not intended to necessarily depict the most preferred embodiments of the invention, nor are the examples meant to be limiting in the sense of the general scope of the overall method.
Example 1 Figure 7 (Structure 12) represents an analog of atropine that has an appended external ester metabophore. It has been designed for delivery as drops to the eye where it will then display its characteristic antimuscarinic properties that are useful during eye examinations for only about 30 minutes. Atropine's several hour duration is in large excess of the type typically needed to conduct a routine eye exam and chemical antidotes often need to be administered so that a patient's vision can be more quickly normalized. In addition, due to the same metabolic programming, the soft drug analog has a better systemic side-effect profile than atropine because the soft drug that is absorbed from this localized topical compartment is readily deactivated.
Example 2
Figures 8 and 9 (Structures 13 and 14) represent metabophore- containing, bulky analogs of decamethonium and pancuronium, respectively. Two external esters have been deployed in each case in order to further enhance the overall molecules' metabolic biotransformations given that these esters' close placements to the bulky aromatic rings slow their individual metabolic hydrolyses rates. The parent compounds' inherent anti- nicotinic activities, produced in a non-depolarizing fashion at neuromuscular junctions by virtue of the presence of the bulky functionalities, has a short half-life due to the appended metabophores. These compounds are ideally suited for use during surgery where there is a long-standing need for titrable, short-acting, non-depolarizing neuromuscular junction blocking agents: Approaches to Short-Acting Neuromuscular Blocking Agents: Nonsymmetrical Bistetrahydroisoquinolinium Mono- and Diesters, N.C Dhar, R.B. Maehr, L.A. Masterson, J.M. Midgley, J.B. Stenlake and W.B. Wastila, J. Med. Chem.. 39, 556 (1996).
Example 3
Figures 10 and 11 (Structures 15 and 16) represent metabophore- containing analogs of prazosin and indoramin, respectively. Figure 10 contains a single sulfonate ester appendage while Figure 11 contains both an internal carboxylate metabophore and an external phosphonate ester appendage. In both cases, the inherent αi -receptor antagonist properties are displayed as an ultra-short duration such that both compounds are better used in critical care settings via the intravenous route to treat hypertensive crises, shock or Raynaud's disease.
Example 4
Emergency room medical practice requires a titrable, quickly equilibrating and short action version of clonidine, Structure 9 in Fig. 4. This drug is also an α-adrenergic receptor ligand. Consideration of the structure- activity relationships for this family of centrally action α∑-adrenergic agonists indicated that while the two ortho-chloro substituents are important for establishing a twisted conformation required at central a2receptors, the para-position is amenable to structural modifications. Principles of Medicinal Chemistry, W.O. Foye, T.L. Lemke, D.A. Williams; Eds., Williams & Wilkins Publ., Baltimore, MD, p. 356 (1995). Incorporation of a single external ester metabophore according to the structural blueprint provided in Fig. 3 affords Structure 8 in Fig. 4. Since Structure 8 is a more lipophilic version of the parent structure, it equilibrates more quickly into the CNS when administered by the IV route. Thereafter, the modified soft drug version possesses a very short pharmacological half-life due to the metabolic liability of the added ester link coupled with the foreign look that its resulting metabolite displays to the a-adrenergic receptor, e.g. a full- blown carboxylate anion in a region otherwise present as a lipophilic aryl moiety. In addition, the titratable, short-acting analog is useful toward affecting the controlled withdrawal of these types of parent compounds which, in turn, are useful toward preventing 'rebound' hypertension. The structural similarities between the clonidine Structure 9, target molecule Structure 8 and the prototypical esmolol Structure 2 are all shown in Fig. 4 in a side-by-side fashion.
Example 5 Figures 12 and 13 (Structures 17 and 18) represent metabophore- containing analogs of phenytoin and carbamazepine, respectively. Both compounds contain two external ester metabophores which serve to prompt a rapid hydrolytic-based metabolic clearance of the compounds. Because of the programmed and controlled elimination, both analogs are able to negate the present high degree of variance found in the metabolism of the parent drugs, e.g. phenytoin saturates its metabolizing systems and thus its metabolism tends to slow down with time while carbamazepine induces its metabolizing enzymes and its metabolism tends to speed up with continued usage. Both of the parent compounds inhibit the sodium channel and find use in the treatment of seizures. As re-designed according to the inventive method's blueprint, these desirable properties are preserved within the soft drug analogs. Further chemical adjustment of the esters' immediate steric environments within each of the analogs are able to program a specific duration of action and elimination which is then also paired with the rate of drug released from sustained-released or implantable' dosage forms so that very even levels of the modified drug's concentrations are achieved for prolonged periods of time.
Example 6 Figure 14 (Structure 19) represents a metabophore-containing analog of enalaprilat. It's external aralkyl ester appendage provides a ready handle for hydrolytic metabolism and thus renders the molecule a short-acting versions of the common ACE-inhibitor, providing that the resulting acidic moiety is not well tolerated when generated in this particular location. Ultimately, an effective soft drug versions is conveniently deployed by the intravenous route and, having drip-rate control of its actions, used more advantageously within critical care settings.
Example 7
Figures 15 and 16 (Structures 20 and 21) represent metabophore- containing analogs of diphenhydramine and famotidine, respectively. In Figure 15 an internal ester has been deployed while in Figure 16 an external ester has been deployed. Because of the metabophoric placements, these analogs are short acting versions of their respective Hi-receptor blocker and
H2-receptor blocker parent compounds. The aralkyl ester soft drugs are beneficial toward use in critical care settings as quickly titrable and controllable, ultra-short-acting agents when given by intravenous infusion.
Example 8 Figure 17 (Structure 22) represents a titrable, quickly equilibrating and ultra-short acting version of theophylline for use in critical care settings whenever an adenosine antagonist is useful, e.g. improving airway resistance in critical neonatal and pediatric populations.
Example 9 Figure 18 (Structure 23) represents a titrable, quickly equilibrating and ultra-short acting version of indomethacin for use in critical care settings whenever an intra-venous anti-inflammatory agent is useful.
Example 10 Figure 19 (Structure 24) represents a titrable, quickly equilibrating and ultra-short acting versions of lidocaine, a Class IB antiarhythmic agent. The aralkyl soft drug allows for more consistent does-response relationships compared to the parent drug when used by the intravenous route in critical care settings.
Example 11 Figures 20 and 21 (Structures 25 and 26) represent titrable, quickly equilibrating and ultra-short acting versions of the calcium channel blockers nifedipine and verapamil, respectively. Figure 20 contains a single, external ester metabophore while Figure 21 contains an internal ester, as well as a pair of external ester, metabophores. Both analogs are ideally suited for use in the critical care arena, including neonatal populations.
Example 12 Figures 22, 23, 24 and 25 (Structures 27, 28, 29, and 30) represent metabophore-containing analogs of sulfamethσxazole, ampicillin, cephalexin and tetracycline, respectively. All of these antibiotics are designed to exhibit ultra-short durations of action which are useful not only in critical care settings via intravenous infusion, but are useful toward localization of their effects within the vicinity of polymeric materials used as sutures or other wound-healing implantables wherein the latter have been impregnated with any one or more of these types of antibiotic soft drugs. Toward easier elaboration of all of the methods of administration, all of the analogs are also designed so as to exhibit good aqueous solubility and stability when formulated as their acidified salts, e.g. as the hydrochloride salts of their amines.
Example 13 The use of methotrexate (Structure 10 in Fig. 6) for treating both epidermoid cancers and severe psoriasis is an ideal situation in which to deploy the metabophore method of the present invention so as to eliminate systemic toxicity upon percutaneous absorption after topical treatments: The Physicians Desk Reference (PDR) 50th ed., Publ: Med. Econ. Co., Montvale, NJ, p. 1276 (1996). Well-established structure-activity relationships reveal that there are three structural components which are required for the interaction of methotrexate with its biological receptor, the latter being the enzyme dihydrofolate reductase (DHFR). Therefore, placement of a labile ester metabophore between any two or these elements (e.g. internal ester) results in inactive metabolites upon hydrolysis of the metabophore. This situation is shown in Fig. 5 where the Structure 10 is depicted in its interaction with DHFR: D.A. Matthews, et al., Science. 297, 452 (1997). The importance of the two glutamate carboxyl groups relative to the rest of the molecule is clear, as is the rather non-demanding region immediately surrounding the glutamate-p-aminobenzoic acid amide bond. Thus, replacement of this amide bond with that of an ester is tolerable for activity, yet allows for placement of a preferred internal-ester type metabophore unit that when hydrolyzed, inactivates the parent molecule. A side-by-side structural comparison between methotrexate, Structure 10, and its internal ester metabophore version, soft drug Structure 11 , is provided in Fig. 6.
Example 14 Figure 26 shows Structures I to VII which represent quickly equilibrating, short acting versions of the α-adrenergic receptor ligand tolazoline. In these structures: X = -COO-, -SO2O- or -PO(OR')O-p; Y = H, CH3, OH or OR'; R' = CH3, CH2CH3 or CH(CH3)2; n = 0, 1 or 2; and, lines drawn into the central portions of either the phenyl or dihydro-imidazole ring systems indicate that the attachment of that group can occur at any one of the ring's un-substituted carbon atoms by replacement of a hydrogen atom. Structure VIII represents a specific version of Structure I wherein X « -COO- , Y = H, R' = CH3, n a 2, and the attached group is substituted for a hydrogen atom that was bonded to the carbon atom located in the para- position of the phenyl ring system. These types of compounds can be administered to humans by the intravenous route during critical care situations. In particular, they are useful in treating persistent pulmonary hypertension of newborns, a condition that, when not successfully treated, can become critical and then has a high incidence of mortality.
Example 15 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydoxy or methoxy groups attached to an inherent phenyl ring system therein, and is modified by connecting one or more of a predetermined chemical arrangement to the inherent phenyl ring system. The chemical arrangement comprises: R— -X— R' where R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly connected to any un- substituted carbon atom within the inherent phenyl ring system;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage; and
R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans.
In certain embodiments, one predetermined chemical arrangement is added and R is an ethyl chain, X is a carboxyl function, and R' is a methyl group.
Example 16 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting one or more of a predetermined chemical arrangement to an inherent dihydro-imidazole ring system therein. The chemical arrangement comprises: φ — R— X — R' where φ is a phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the inherent dihydro-imidazole ring system;
R is an alkyl, or alkenyl containing chain either branched or unbranched from 0 to 10 carbons that is connected to φ via a metabolically stable linkage;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage; and,
R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans.
In certain embodiments, at least one predetermined chemical arrangement is added and φ is a phenyl ring, R is an ethyl chain, X is a carboxyl function, and R' is a methyl group.
Example 17 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring therein, and is modified by incorporating one predetermined chemical arrangement between an inherent phenyl ring system and an inherent dihydro-imidazole ring system therein. The chemical arrangement comprises: X—R' where X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring system via respective carbon, sulfur or phosphorous atoms; and,
R' is the inherent dihydro-imidazole ring system that is connected to one of oxygen atoms present in X via a 2-position carbon atom. In certain embodiments, X is a carboxyl group. Example 18 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting a first chemical arrangement to the inherent phenyl ring system and by connecting a second chemical arrangement to an inherent dihydro-imidazole ring system. The chemical arrangements comprises: φ_R_X_ > where φ is the inherent phenyl ring system in the first chemical arrangement, and is an added phenyl substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the dihydro-imidazole ring system in the second chemical arrangement;
R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly connected to any un- substituted carbon atom within the inherent phenyl ring system in the first chemical arrangement and within the phenyl, substituted aryl or heteroaryl system of the added φ in the second chemical arrangement;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage in the first and second chemical arrangements; and,
R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans in the first and second chemical arrangements. In certain embodiments, the φ is a phenyl ring of the dihydro- imidazole connection in the second chemical arrangement, R is an ethyl group in both the first and second chemical arrangements, X is a carboxyl function in the first and second chemical arrangements, and R' is a methyl group in the first and second chemical arrangements. Example 19 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting a first chemical arrangement to the inherent phenyl ring system and by incorporating a second chemical arrangement between the inherent phenyl ring system and an inherent dihydro-imidazole ring. The chemical arrangements comprise: R — X — R' where R is absent for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to any un- substituted carbon within the inherent phenyl ring system in the first chemical arrangement; X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring system via respective carbon, sulfur or phosphorous atoms for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is connected to R via a metabolically stable linkage; and, R' is the inherent dihydro-imidazole system that is connected to one of oxygen atoms present in X via a 2-position carbon atom for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans for the connection of the first chemical arrangement to the phenyl ring system.
In certain embodiments, R is an ethyl group and R' is a methyl group or the inherent phenyl ring system in the first chemical arrangement, and X is a carboxyl function in the first and second chemical arrangements. Example 20 In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting a first chemical arrangement to an inherent dihydro-imidazole ring system and by incorporating a second chemical arrangement between the inherent phenyl ring system and the inherent dihydro-imidazole ring. The first and second chemical arrangements comprise: φ — R— X— -R' where φ is the inherent phenyl of the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is a phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the dihydro- imidazole ring system in the first chemical arrangement;
R is absent for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl or alkylene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to any un-substituted carbon within the added φ system in the first chemical arrangement;
X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring via respective carbon, sulfur or phosphorous atoms for the incorporation between the phenyl ring system and the dihydro-imidazole ring system, and is connected to R via a metabolically stable linkage; and
R' is the inherent dihydro-imidazole ring system that is connected to one of oxygen atoms present in X via the 2-position carbon for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing form 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans for the connection of the predetermined chemical arrangement to the dihydro- imidazole ring system in the first chemical arrangement. In certain embodiments, the φ is a phenyl ring, R is an ethyl and R' is a methyl for the connection to the dihydro-imidazole ring system in the first chemical arrangement, and X is a carboxyl function in both in the first and second chemical arrangements.
Example 21
In certain embodiments, the composition of matter comprises at least one of tolazoline or its derivatives and having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, and is modified by connecting a first predetermined chemical arrangement to the inherent phenyl ring system, connecting a second predetermined chemical arrangement to an inherent dihydro-imidazole ring system, and incorporating a third chemical arrangement between the inherent phenyl ring system and the inherent dihydro-imidazole ring system. The first, second and third chemical arrangements comprise: φ— -R— -X— R' where φ is the inherent phenyl in the first chemical arrangement and for incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is either an added phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the inherent dihydro-imidazole ring system in the second chemical arrangement;
R is absent for incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to an un-substituted carbon within the inherent phenyl ring system in the first chemical arrangement, and is separately attached to an un-substituted carbon within the added phenyl ring system in the second chemical arrangement;
X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring via the respective carbon, sulfur or phosphorous atoms for the incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is connected to R via a metabolically stable linkage for both the first and second chemical arrangements; and,
R' is the inherent dihydro-imidazole ring system that is connected to one of the oxygen atoms present in X via the 2-position carbon atom for the incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans for both the first and second chemical arrangements.
In certain embodiments, the φ is a phenyl for the dihydro-imidazole connection in the second chemical arrangement, R is an ethyl group for the connection to both the inherent and added phenyl rings in the first and second chemical arrangements, respectively, and X is a carboxyl function of the first, second, and third chemical arrangements, and R' is a methyl group for the first and second chemical arrangements.
Example 22
In certain embodiments, the programmed metabolism of the added chemical arrangement circumvents one or more toxic metabolic pathways.
The programmed rate of metabolism of the added chemical arrangement is capable of being adjusted so as to produce a shorter duration of action for the modified drug as compared to the parent drug. The shorter duration allows the modified drug to be under precise moment-to-moment control by adjustment of an infusion rate of the modified drug when administered intravenously. In certain embodiments, the intravenous administration is used to treat critical care neonates.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatment, molecules and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims. Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
Having described presently preferred embodiments of the invention, it is to be understood that there may be other embodiments which are within the scope of the appended claims.

Claims

CLAIMSWe claim:
1. A method for treating persistent pulmonary hypertension in human newborns comprising deploying an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious parent drug compound so as to retain efficacy while re-directing a preferred route and rate of the parent drug compound's metabolism to an inactive or very weakly active and non-toxic metabolite, the chemical arrangement comprising: φ— R— X— R' wherein φ is a phenyl, substituted aryl or heteroaryl system that is already present in the parent drug compound or is specifically added to the parent drug compound via a metabolically stable connection;
R is an alkly or alkene containing chain either branched or unbranched from 0 to 10 carbons that is already present in the parent drug compound or is added to the parent drug compound via a metabolically stable connection to φ;
X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via a metabolically stable connection to R; and
R' is an added alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to10 carbons, or is a structural element already present as an inherent portion of the parent drug compound.
2. The method of claim 1, in which the parent compound comprises an alpha-adrenergic receptor ligand.
3. The method of claim 2, in which the alpha-adrenergic receptor ligand has an inherent phenyl ring system and comprises tolazoline or is a derivative of tolazoline wherein the inherent phenyl system is also substituted with one or more methyl, hydroxy or methoxy groups in any combination of attachments to any of ortho-, meta-, or para- positions on the inherent phenyl ring system.
4. A composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system therein, the composition being modified by one or more of a predetermined chemical arrangement connected to the inherent phenyl ring system, the chemical arrangement comprising:
R_X_R' wherein R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly connected to any un-substituted carbon atom within the inherent phenyl ring system;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage; and R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans.
5. The composition of claim 4, wherein one predetermined chemical arrangement is added and wherein R is an ethyl chain, X is a carboxyl function, and R' is a methyl group.
6. A composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, the composition being modified by one or more of a predetermined chemical arrangement connected to an inherent dihydro-imidazole ring system therein, the chemical arrangement comprising: φ— R—X_R' wherein φ is a phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the inherent dihydro-imidazole ring system;
R is an alkyl, or alkenyl containing chain either branched or unbranched from 0 to 10 carbons that is connected to φ via a metabolically stable linkage;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage; and,
R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans.
7. The composition of claim 6, wherein at least one predetermined chemical arrangement is added and wherein φ is a phenyl ring, R is an ethyl chain, X is a carboxyl function, and R' is a methyl group.
8. A composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring therein, the composition being modified by one predetermined chemical arrangement incorporated between an inherent phenyl ring system and an inherent dihydro-imidazole ring system therein, the chemical arrangement comprising:
X— ' wherein X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring system via respective carbon, sulfur or phosphorous atoms; and,
R' is the inherent dihydro-imidazole ring system that is connected to one of oxygen atoms present in X via a 2-position carbon atom.
9. The composition in claim 8, wherein X is a carboxy group.
10. A composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, the composition being modified by a first chemical arrangement connected to the inherent phenyl ring system and by a second chemical arrangement connected to an inherent dihydro-imidazole ring system, the chemical arrangements comprising: φ_R_„X— R' wherein φ is the inherent phenyl ring system in the first chemical arrangement, and is an added phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the dihydro-imidazole ring system in the second, chemical arrangement;
R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly connected to any un- substituted carbon atom within the inherent phenyl ring system in the first chemical arrangement and within the phenyl, substituted aryl or heteroaryl system of the added φ in the second chemical arrangement;
X is a carboxyl, sulfoxyl or phosphatyl function that is connected to R via a metabolically stable linkage; and,
R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans.
11. The composition in claim 10, wherein φ is a phenyl ring for the dihydro-imidazole connection in the second chemical arrangement, R is an ethyl group in both the first and the second chemical arrangements, X is a carboxyl function in both the first and the second chemical arrangements, and R' is a methyl group in both the first and the second chemical arrangements.
12. A composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, the composition being modified by a first chemical arrangement connected to the inherent phenyl ring system and by a second chemical arrangement incorporated between the inherent phenyl ring system and an inherent dihydro-imidazole ring, the chemical arrangements comprising:
R_X—R' wherein R is absent for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to any un-substituted carbon within the inherent phenyl ring system in the first chemical arrangement; X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring system via respective carbon, sulfur or phosphorous atoms for the incorporation between the inherent phenyl ring system and the inherent dihydro-imidazole ring in the second chemical arrangement, and is connected to R via a metabolically stable linkage; R' is the inherent dihydro-imidazole system that is connected to one of oxygen atoms present in X via a 2-position carbon atom for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons that is connected to X via a linkage that is labile toward metabolism by humans for the connection of the first chemical arrangement to the phenyl ring system.
13. The composition in claim 12, wherein R is an ethyl group and R' is a methyl group for the inherent phenyl ring system in the first chemical arrangement, and X is a carboxyl function in both the first and the second chemical arrangements.
14. The composition comprising at least one of tolazoline or its derivatives having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, the composition being modified by a first chemical arrangement connected to an inherent dihydro-imidazole ring system and by a second chemical arrangement incorporated between the inherent phenyl ring system and the inherent dihydro-imidazole ring, the first and second chemical arrangements comprising: φ— —X— R' wherein φ is the inherent phenyl for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is a phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the dihydro- imidazole ring system in the first chemical arrangement;
R is absent for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl or alkylene containing chain either branched or unbranched from 0 to10 carbons that is directly attached to any un-substituted carbon within the added φ system in the first chemical arrangement;
X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring via respective carbon, sulfur or phosphorous atoms for the incorporation between the phenyl ring system and the dihydro-imidazole ring system, and is connected to R via a metabolically stable linkage;
R' is the inherent dihydro-imidazole ring system that is connected to one of oxygen atoms present in X via a 2-position carbon for the incorporation between the phenyl ring and the dihydro-imidazole ring in the second chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans for the connection of the predetermined chemical arrangement to the dihydro- imidazole ring system in the first chemical arrangement.
15. The composition in claim 14, wherein φ is a phenyl ring, R is an ethyl and R' is a methyl for the connection to the dihydro-imidazole ring system in the first chemical arrangement, and X is a carboxyl function in both in the first and the second chemical arrangements.
16. A composition comprising at least one of tolazoline or its derivatives and having one or more methyl, hydroxy or methoxy groups attached to an inherent phenyl ring system, the composition being modified by a first predetermined chemical arrangement connected to the inherent phenyl ring system, a second predetermined chemical arrangement connected to an inherent dihydro-imidazole ring system, and a third chemical arrangement incorporated between the inherent phenyl ring system and the inherent dihydro-imidazole ring system, the first, second and third chemical arrangements comprising: φ— R—X— R' wherein φ is the inherent phenyl in the first chemical arrangement and for incorporation between the phenyl ring and the dihydro- imidazole ring in the third chemical arrangement, and is either an added phenyl, substituted aryl or heteroaryl system that is directly connected to any un-substituted carbon atom within the inherent dihydro-imidazole ring system in the second chemical arrangement;
R is absent for incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is directly attached to an un-substituted carbon within the inherent phenyl ring system in the first chemical arrangement and is separately attached to an un-substituted carbon within the added phenyl ring system in the second chemical arrangement; X is a carboxyl, sulfoxyl or phosphatyl function that is directly connected to the inherent phenyl ring via the respective carbon, sulfur or phosphorous atoms for the incorporation between the phenyl ring and the dihydro-imidazole ring in the third chemical arrangement, and is connected to R via a metabolically stable linkage for both the first and the second chemical arrangements; R' is the inherent dihydro-imidazole ring system that is connected to one of the oxygen atoms present in X via a 2-position carbon atom for the incorporation between the phenyl ring and the dihydro- imidazole ring in the third chemical arrangement, and is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons connected to X via a linkage that is labile toward metabolism by humans for both the first and second chemical arrangements.
17. The composition in claim 16, wherein φ is a phenyl for the dihydro-imidazole connection in the second chemical arrangement, R is an ethyl group for the connection to both the inherent and the added phenyl rings in the first and the second chemical arrangements, respectively, X is a carboxyl function for the first, the second, and the third chemical arrangements, and R' is a methyl group for the first and the second chemical arrangements.
18. The method of claim 1, in which the programmed metabolism of the added chemical arrangement circumvents one or more toxic metabolic pathways.
19. The method of claim 1, in which a programmed rate of metabolism for the added chemical arrangement is adjusted so as to produce a shorter duration of action for the modified drug as compared to the parent drug.
20. The method of claim 19, in which the shorter duration allows the modified drug to be under moment-to-moment control by adjustment of an infusion rate of the modified drug when administered intravenously.
21. The method of claim 20, in which the intravenous administration is used to treat critical care neonates.
PCT/US2003/036686 2002-11-18 2003-11-17 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs Ceased WO2004045533A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003291007A AU2003291007A1 (en) 2002-11-18 2003-11-17 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
JP2004553810A JP2006508984A (en) 2002-11-18 2003-11-17 Methods and compositions for treating persistent neonatal pulmonary hypertension using aralkyl ester soft drugs
EP03783592A EP1565178A2 (en) 2002-11-18 2003-11-17 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
CA002503312A CA2503312A1 (en) 2002-11-18 2003-11-17 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/299,044 2002-11-18
US10/299,044 US6756047B2 (en) 2000-05-12 2002-11-18 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs

Publications (2)

Publication Number Publication Date
WO2004045533A2 true WO2004045533A2 (en) 2004-06-03
WO2004045533A3 WO2004045533A3 (en) 2004-07-29

Family

ID=32324371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036686 Ceased WO2004045533A2 (en) 2002-11-18 2003-11-17 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs

Country Status (6)

Country Link
US (2) US6756047B2 (en)
EP (1) EP1565178A2 (en)
JP (1) JP2006508984A (en)
AU (1) AU2003291007A1 (en)
CA (1) CA2503312A1 (en)
WO (1) WO2004045533A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
CN101678033A (en) * 2007-02-09 2010-03-24 联合治疗公司 Treprostinil treatment for interstitial lung disease and asthma
US10793519B2 (en) 2018-05-02 2020-10-06 Academic Pharmaceuticals Incorporated Ultra short acting anti-arrhythmic agents

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387103A (en) 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4405642A (en) 1980-11-28 1983-09-20 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4450173A (en) 1980-11-28 1984-05-22 American Hospital Supply Corporation Compounds and method for treatment or prophylaxis of cardiac disorders
US4508725A (en) 1982-12-22 1985-04-02 American Hospital Supply Corporation Esters of 3-(3-substituted-amino-2-hydroxypropoxy)-4-substituted-1,2,5-thiadiazole derivatives
US4556668A (en) 1983-07-15 1985-12-03 American Hospital Supply Corporation Ethylenediamine derivatives of aryloxypropanolamine aryl esters having various medicinal properties
US4593119A (en) 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4604481A (en) 1980-11-28 1986-08-05 American Hospital Supply Corporation Compounds for treatment or prophylaxis of cardiac disorders
US4623652A (en) 1981-11-12 1986-11-18 American Hospital Supply Corporation Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3150137A (en) * 1964-09-22 Carbamate derivative of s-hydroxy-
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
US4304781A (en) * 1978-11-30 1981-12-08 John Wyeth & Brother Limited Treatment of ulcers and hypertension
US4906661A (en) * 1981-11-12 1990-03-06 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
US4692446A (en) * 1981-11-12 1987-09-08 E. I. Du Pont De Nemours & Co., Inc. Esters of aryloxypropanolamine derivatives and medicinal uses
US4804677A (en) * 1981-11-12 1989-02-14 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
US4505926A (en) * 1983-09-15 1985-03-19 Beecham Group P.L.C. Quaternary amino imidazolidines, compositions and use
FI91859C (en) 1987-06-17 1994-08-25 Eisai Co Ltd Analogue method for the preparation of an active benzothiazole derivative as an antiallergic agent
US5364880A (en) * 1993-06-16 1994-11-15 Advanced Therapies, Inc. Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
US6316487B1 (en) * 1993-06-16 2001-11-13 Aryx Therapeutics Compounds for treatment of cardiac arrhythmia synthesis, and methods of use
US6159665A (en) * 1993-06-17 2000-12-12 Lucent Technologies Inc. Processes using photosensitive materials including a nitro benzyl ester photoacid generator
US6114344A (en) * 1998-07-16 2000-09-05 Aryx Therapeutics Long-acting local anesthetics
US6683195B2 (en) * 1999-10-15 2004-01-27 Aryx Therapeutics Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
US6362223B1 (en) * 1999-10-15 2002-03-26 Aryx Therapeutics Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
AU5723001A (en) * 2000-04-24 2001-11-07 Aryx Therapeutics Ultrashort acting hypnotic barbiturates
CA2405025A1 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US6750238B1 (en) * 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
WO2002024689A1 (en) * 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
SE0004229D0 (en) * 2000-11-17 2000-11-17 Aga Ab Inhalation of nitric oxide
AU2002243643A1 (en) * 2001-01-25 2002-08-06 Yale University Estradiol-16alpha-carboxylic acid esters as locally active estrogens
EP1383730A2 (en) * 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinergic compounds and methods of use
EP1414798A2 (en) * 2001-04-03 2004-05-06 Aryx Therapeutics Ultrashort-acting opioids for transdermal application

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387103A (en) 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4405642A (en) 1980-11-28 1983-09-20 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4450173A (en) 1980-11-28 1984-05-22 American Hospital Supply Corporation Compounds and method for treatment or prophylaxis of cardiac disorders
US4593119A (en) 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4604481A (en) 1980-11-28 1986-08-05 American Hospital Supply Corporation Compounds for treatment or prophylaxis of cardiac disorders
US4623652A (en) 1981-11-12 1986-11-18 American Hospital Supply Corporation Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
US4508725A (en) 1982-12-22 1985-04-02 American Hospital Supply Corporation Esters of 3-(3-substituted-amino-2-hydroxypropoxy)-4-substituted-1,2,5-thiadiazole derivatives
US4556668A (en) 1983-07-15 1985-12-03 American Hospital Supply Corporation Ethylenediamine derivatives of aryloxypropanolamine aryl esters having various medicinal properties

Also Published As

Publication number Publication date
AU2003291007A1 (en) 2004-06-15
US6756047B2 (en) 2004-06-29
AU2003291007A8 (en) 2004-06-15
WO2004045533A3 (en) 2004-07-29
US20030130236A1 (en) 2003-07-10
EP1565178A2 (en) 2005-08-24
US20040224925A1 (en) 2004-11-11
JP2006508984A (en) 2006-03-16
CA2503312A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DE60300021T2 (en) que-
MXPA06004076A (en) Method for the production of amino crotonyl compounds.
US20070135505A1 (en) Aralkyl ester soft drugs
US7049326B2 (en) Method and compositions for temporarily incapacitating subjects
GB2083476A (en) Heterocyclic compounds
CN101020661A (en) (-)-meptazinol carbamate derivative and/or its salt and their prepn and use
US6756047B2 (en) Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
JP2001524478A (en) 5- (2-imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha adrenergic receptor agonists with improved metabolic stability
CN101215258A (en) Dihydropyridine calcium antagonist compound and its preparation method and medical application
DE60001100T2 (en) BENZAMIDE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
WO2004054965A1 (en) Drugs for chronic pain
NO124309B (en)
GB2182935A (en) Quinoline derivatives
US4061760A (en) Method for using 3-substituted-5-phenyl-5-pyridyl hydantoins as antiarrhythmic agents
US6232323B1 (en) Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same
EP2238108B1 (en) Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
WO2012000881A1 (en) Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US6413990B1 (en) Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity
DE19511916A9 (en) New N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
JPS59500672A (en) Novel carboxamide guanidine, its production method, and pharmacological composition containing the same
JPWO2006025471A1 (en) Piperidine derivatives or pharmaceutically acceptable salts thereof
HK1095817B (en) Method for the production of amino crotonyl compounds
PL213871B1 (en) N1- aryl piperazine alkyl derivatives of 5,5 - diphenylhydantoin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2503312

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004553810

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003783592

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783592

Country of ref document: EP